Corcept Therapeutics (NASDAQ:CORT) Shares Gap Up After Insider Buying Activity

Corcept Therapeutics Incorporated (NASDAQ:CORT) gapped up prior to trading on Friday following insider buying activity. The stock had previously closed at $34.08, but opened at $35.50. Corcept Therapeutics shares last traded at $36.2060, with a volume of 409,583 shares traded.

Specifically, Director G Leonard Baker, Jr. bought 100,000 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was purchased at an average cost of $33.14 per share, with a total value of $3,314,000.00. Following the purchase, the director directly owned 1,146,631 shares of the company’s stock, valued at $37,999,351.34. This trade represents a 9.55% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Wall Street Analyst Weigh In

CORT has been the topic of a number of analyst reports. HC Wainwright reduced their price target on Corcept Therapeutics from $105.00 to $67.00 and set a “buy” rating on the stock in a research report on Friday, February 20th. Wolfe Research downgraded Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price objective for the company. in a research report on Wednesday, December 31st. Canaccord Genuity Group upped their target price on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, January 23rd. UBS Group started coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 target price on the stock. Finally, Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $77.17.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Director G. Leonard Baker Jr. bought 100,000 shares (~$3.3M) at about $33.14 on March 17, a meaningful insider purchase that signals management confidence and can support short‑term demand. Read More.
• Neutral Sentiment: Short‑interest reports for March 19–20 show effectively zero reported short interest (days‑to‑cover ≈ 0), which appears anomalous and likely reflects reporting quirks rather than a genuine absence of short sellers; this creates uncertainty about short‑seller pressure signals.
• Negative Sentiment: Multiple shareholder‑rights firms (Hagens Berman, Schall, DJS, Pomerantz, Rosen, Glancy, others) have issued class‑action/lead‑plaintiff notices tied to alleged FDA issues and a federal court patent loss — a concentrated legal PR wave that raises litigation risk, could increase future liabilities, and likely weighs on investor confidence. Read More. Read More.
• Negative Sentiment: Zacks Research sharply cut EPS forecasts across 2026–2027 and maintains a “Strong Sell” stance — analyst downgrades and lower near‑term earnings expectations increase downside pressure on valuation and can amplify selling if guidance or legal exposure worsens. Read More.

Corcept Therapeutics Price Performance

The company has a market capitalization of $3.68 billion, a PE ratio of 42.24 and a beta of 0.29. The company has a current ratio of 2.92, a quick ratio of 2.85 and a debt-to-equity ratio of 0.01. The stock has a fifty day simple moving average of $37.46 and a 200-day simple moving average of $61.87.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The business had revenue of $202.13 million during the quarter, compared to analysts’ expectations of $254.94 million. During the same quarter in the previous year, the company posted $0.26 EPS. The company’s revenue was up 11.1% compared to the same quarter last year. Equities analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 earnings per share for the current year.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds have recently added to or reduced their stakes in CORT. Torren Management LLC acquired a new stake in Corcept Therapeutics during the fourth quarter worth approximately $25,000. Advisory Services Network LLC acquired a new position in shares of Corcept Therapeutics in the 3rd quarter valued at $25,000. Clearstead Advisors LLC grew its position in shares of Corcept Therapeutics by 163.6% in the 3rd quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 193 shares during the last quarter. Atlas Capital Advisors Inc. purchased a new position in shares of Corcept Therapeutics in the 4th quarter valued at $31,000. Finally, Hantz Financial Services Inc. raised its stake in Corcept Therapeutics by 113.7% during the 4th quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 524 shares in the last quarter. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.